CAPTRUST Financial Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,994	Closed	-$4K	–	4399
2022 Q2	$4K	Buy	1,994 +482	+32%	+$1.05K	﹤0.01%	4241
2022 Q1	$4K	Buy	1,512 +686	+83%	+$2.58K	﹤0.01%	4308
2021 Q4	$4K	Hold	826	–	–	﹤0.01%	4217
2021 Q3	$4K	Hold	826	–	–	﹤0.01%	4069
2021 Q2	$6K	Hold	826	–	–	﹤0.01%	3813
2021 Q1	$6K	Buy	826 +26	+3%	+$187	﹤0.01%	3684
2020 Q4	$5K	Hold	800	–	–	﹤0.01%	2881
2020 Q3	$4K	Hold	800	–	–	﹤0.01%	2614
2020 Q2	$4K	Buy	+800	New	+$3.55K	﹤0.01%	2468

Other funds holding PRTK

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Bruce & Co Chicago, Illinois $350M AUM 33.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

1CM

1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return

CAPTRUST Financial Advisors's PRTK Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2022, closing a stake of 1,994 shares — an estimated $4K sold.

CAPTRUST Financial Advisors first reported a position in PRTK in Q2 2020 and held it in 9 quarters. The position peaked at $6K in Q2 2021. 72 funds tracked by Wall St. Rank hold PRTK as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 1,994 Paratek Pharmaceuticals, Inc. shares in Q3 2022, an estimated $4K.
CAPTRUST Financial Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2020 and held it in 9 quarters.
CAPTRUST Financial Advisors's Paratek Pharmaceuticals, Inc. position peaked at $6K in Q2 2021.
72 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.